MAFLD - Diagnosis of Metabolic Dysfunction Associated Fatty Liver
Disease
The latest guidelines proposed by International Expert
Consensus are used for the clinical diagnosis of Metabolic
Associated Fatty Liver Disease (MAFLD). The new definition
takes hepatic steatosis (determined by elastography or
histology or biomarker-based fatty liver index) as a major
criterion. In addition, race, gender, body mass index (BMI),
waist circumference (WC), fasting plasma glucose (FPG),
systolic blood pressure (SBP), diastolic blood pressure (DBP),
triglycerides (TG), high-density lipoprotein cholesterol
(HDLC), homeostatic model assessment of insulin resistance
(HOMAIR), high sensitive c-reactive protein (HsCRP) for the
diagnosis of MAFLD. Each parameter has to be interpreted based
on the proposed cut-offs, making the diagnosis slightly complex
and error-prone. This package is developed by incorporating the
latest international expert consensus guidelines, and it will
aid in the easy and quick diagnosis of MAFLD based on FibroScan
in busy healthcare settings and also for research purposes. The
new definition for MAFLD as per the International Consensus
Statement is described by Eslam M et al (2020).
<doi:10.1016/j.jhep.2020.03.039>.
